# Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma

> **NCT00002560** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 40 (estimated)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** monoclonal antibody 3F8
- **BIOLOGICAL:** sargramostim

## Key facts

- **NCT ID:** NCT00002560
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-02
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2013-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002560, "Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*